Kite Pharma's flagship product, Yescarta (axicabtagene ciloleucel), received FDA approval in 2017 for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Another CAR-T product, Tecartus (brexucabtagene autoleucel), was approved in 2020 for the treatment of relapsed or refractory mantle cell lymphoma.
